Tokyo, June 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061753) titled 'Cardiovascular diseases in COPD patients with severe acute exacerbations: the prevalence and early identification of undiagnosed cardiac comorbidities- A prospective observational study' on May 31.

Study Type: Observational

Primary Sponsor: Institute - Taipei Veterans General Hospital

Condition: Condition - Cardiovascular diseases (CVD), including heart failure, ischemic heart disease, arrhythmias, and pulmonary hypertension, are common in patients with COPD and contribute substantially to morbidity and mortality. During acute exacerbations of COPD (AECOPD), cardiovascular events may be overlooked because their symptoms overlap with those of respiratory deterioration. Studies suggest that up to 40% of hospitalized AECOPD patients have unrecognized cardiac comorbidities. However, routine cardiovascular screening is not currently recommended. Exercise-induced desaturation (EID), commonly assessed by the six-minute walk test, is associated with adverse cardiopulmonary outcomes and may serve as a marker of occult cardiovascular dysfunction. Early EID assessment after stabilization of AECOPD may provide a practical approach for identifying previously undiagnosed cardiovascular disease. Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - This prospective observational study aims to determine the prevalence of coexisting cardiovascular diseases, including newly diagnosed and previously unrecognized conditions, in patients hospitalized with severe AECOPD. Basic objectives2 - Others

Eligibility: Age-lower limit - 40 years-old = Gender - Male and Female Key inclusion criteria - 1. Male or female outpatients aged from 40 to 90 years 2. Spirometry confirmed COPD patients (post-bronchodilation FEV1/FVC = 1 year 3. Meet the criteria of severe AECOPD 4. Agree to attend the study and sign informed consent Key exclusion criteria - 1. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease. 2. Hemodynamic instability requiring a life support machine, such as ECMO, IABP 3. Respiratory failure requiring intubation and mechanical ventilation 4. Coexisting medical conditions with a life expectancy of less than 1 year 5. Mental problem or unclear consciousness to obey medical treatment 6. Inability to ambulate or perform walking test Target Size - 104

Recruitment Status: Recruitment status - Enrolling by invitation Date of protocol fixation - 2025 Year 06 Month 20 Day Date of IRB - 2025 Year 08 Month 15 Day Anticipated trial start date - 2026 Year 01 Month 01 Day Last follow-up date - 2026 Year 05 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070668

Disclaimer: Curated by HT Syndication.